[Form 4] Twist Bioscience Corp Insider Trading Activity

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported an insider sale by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On 10/06/2025 Mr. Cho sold 3,876 shares of common stock at a price of $32.187 per share to satisfy tax withholding tied to the vesting of Performance Stock Units (PSUs). After the transaction he beneficially owned 98,710 shares. The filing notes these were mandatory "sell to cover" transactions elected under the company equity plans and are not discretionary trades by the reporting person.

Positive

• Transaction was for tax withholding, not a discretionary sale
• Reporting person retains significant ownership with 98,710 shares after the sale

Negative

• Small reduction in holdings of 3,876 shares
• Sale executed at $32.187, which realized proceeds and modestly increased share float

Insights

Corporate Governance Analyst

TL;DR: A routine "sell to cover" tax withholding sale by an officer; holdings remain material.

The sale of 3,876 shares at $32.187 was executed to fund tax withholding for vested PSUs rather than as a discretionary disposition. Such transactions are common when companies require withholding at vesting and are typically administrative in nature.

Key dependencies include continued vesting schedules and plan withholding policies; monitor future Form 4s for any discretionary sales or changes in equity-plan terms within the next 12 months.

Equity Compensation Specialist

TL;DR: The trade reflects plan mechanics, not a change in executive ownership intent.

Reporting indicates the issuer elected a "sell to cover" method under its equity incentive plans, obligating the sale to satisfy taxes on PSUs. The report clarifies the sale does not represent voluntary liquidation of holdings by the officer.

Investors may watch for the number and timing of future PSU vestings and any variation from "sell to cover" practice over the coming vesting cycles, which could affect share count and potential dilution.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		S		3,876(1)	D	$32.187	98,710	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dennis Cho disclose on the Form 4 for TWST?

He disclosed a sale of 3,876 shares on 10/06/2025 at $32.187 per share to cover taxes from PSU vesting.

Was the sale by the TWST insider discretionary?

No. The filing states the sales were mandatory "sell to cover" transactions required to satisfy tax withholding for vested PSUs.

How many TWST shares does the reporting person own after the transaction?

The reporting person beneficially owned 98,710 shares following the reported transaction.

What is the reporting person's role at Twist Bioscience (TWST)?

The reporting person is Senior Vice President, Chief Legal Officer & Corporate Secretary.

When was the Form 4 filed for this transaction?

The signature block shows the Form 4 was signed on 10/08/2025.